BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Sookoian S, Fernández MA, Castaño G. Effects of six months losartan administration on liver fibrosis in chronic hepatitis C patients: A pilot study. World J Gastroenterol 2005; 11(48): 7560-7563 [PMID: 16437678 DOI: 10.3748/wjg.v11.i48.7560]
URL: https://www.wjgnet.com/1007-9327/full/v11/i48/7560.htm
Number Citing Articles
1
Josephine A. Grace, Chandana B. Herath, Kai Yan Mak, Louise M. Burrell, Peter W. Angus. Update on new aspects of the renin–angiotensin system in liver disease: clinical implications and new therapeutic optionsClinical Science 2012; 123(4): 225 doi: 10.1042/CS20120030
2
Patricio Ibañez, Nancy Solis, Margarita Pizarro, Gloria Aguayo, Ignacio Duarte, Juan Francisco Miquel, Luigi Accatino, Marco Arrese. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitisJournal of Gastroenterology and Hepatology 2007; 22(6): 846 doi: 10.1111/j.1440-1746.2006.04700.x
3
Hyun Ho Yun, Sunyoung Park, Myung-Jin Chung, Ji-Yoon Son, Jae-Min Park, Seung-Jun Jung, Jae-Hyuk Yim, Kyung-Ku Kang, Seongrim Byeon, Su-Min Baek, Seoung-Woo Lee, A-Rang Lee, Tae-Hwan Kim, Jin-Kyu Park, Kyu-Shik Jeong. Effects of losartan and l-serine in a mouse liver fibrosis modelLife Sciences 2021; 278: 119578 doi: 10.1016/j.lfs.2021.119578
4
Yong-Han Paik, Jonghwa Kim, Tomonori Aoyama, Samuele De Minicis, Ramon Bataller, David A. Brenner. Role of NADPH Oxidases in Liver FibrosisAntioxidants & Redox Signaling 2014; 20(17): 2854 doi: 10.1089/ars.2013.5619
5
Erica Novo, Fabio Marra, Maurizio Parola. Studies on Hepatic DisordersOxidative Stress in Applied Basic Research and Clinical Practice 2015; : 171 doi: 10.1007/978-3-319-15539-5_8
6
O. Guillaud, K.C. Gurram, M. Puglia, L. Lilly, O. Adeyi, E.L. Renner, N. Selzner. Angiotensin Blockade Does Not Affect Fibrosis Progression in Recurrent Hepatitis C After Liver TransplantationTransplantation Proceedings 2013; 45(6): 2331 doi: 10.1016/j.transproceed.2013.01.067
7
Amanda M Murphy, Alison L Wong, Michael Bezuhly. Modulation of angiotensin II signaling in the prevention of fibrosisFibrogenesis & Tissue Repair 2015; 8(1) doi: 10.1186/s13069-015-0023-z
8
Jingjing Zhao, Hao Yang, Bo Chen, Rui Zhang. The skeletal renin-angiotensin system: A potential therapeutic target for the treatment of osteoarticular diseasesInternational Immunopharmacology 2019; 72: 258 doi: 10.1016/j.intimp.2019.04.023
9
Ki Tae Suk, Moon Young Kim, Dong Hun Park, Kyu Hong Kim, Ki Won Jo, Jin Hon Hong, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Soon Koo Baik. Effect of Propranolol on Portal Pressure and Systemic Hemodynamics in Patients with Liver Cirrhosis and Portal Hypertension: A Prospective StudyGut and Liver 2007; 1(2): 159 doi: 10.5009/gnl.2007.1.2.159
10
Sadashiva S. Karnik, Hamiyet Unal, Jacqueline R. Kemp, Kalyan C. Tirupula, Satoru Eguchi, Patrick M. L. Vanderheyden, Walter G. Thomas, Eliot H. Ohlstein. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic StimuliPharmacological Reviews 2015; 67(4): 754 doi: 10.1124/pr.114.010454
11
Shuvra Ray, Carlo De Salvo, Theresa T. Pizarro. Central role of IL-17/Th17 immune responses and the gut microbiota in the pathogenesis of intestinal fibrosisCurrent Opinion in Gastroenterology 2014; 30(6): 531 doi: 10.1097/MOG.0000000000000119
12
Adriana L. Burgueño, Tomas F. Gianotti, Noelia G. Mansilla, Carlos J. Pirola, Silvia Sookoian. Cardiovascular disease is associated with high-fat-diet-induced liver damage and up-regulation of the hepatic expression of hypoxia-inducible factor 1α in a rat modelClinical Science 2013; 124(1): 53 doi: 10.1042/CS20120151
13
Paschalis Paschos, Konstantinos Tziomalos. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatmentWorld Journal of Hepatology 2012; 4(12): 327-331 doi: 10.4254/wjh.v4.i12.327
14
Tarek M. Mostafa, Gamal A. El-azab, Gamal A. Badra, Alyaa S. Abdelwahed, Abeer A. Elsayed. Effect of Candesartan and Ramipril on Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection: A Randomized Controlled Prospective StudyCurrent Therapeutic Research 2021; 95: 100654 doi: 10.1016/j.curtheres.2021.100654
15
Marisa Couluris, Brent W. Kinder, Ping Xu, Margaret Gross-King, Jeffrey Krischer, Ralph J. Panos. Treatment of Idiopathic Pulmonary Fibrosis with Losartan: A Pilot ProjectLung 2012; 190(5): 523 doi: 10.1007/s00408-012-9410-z
16
Silvia Sookoian, Carlos J. Pirola. Review article: shared disease mechanisms between non‐alcoholic fatty liver disease and metabolic syndrome – translating knowledge from systems biology to the bedsideAlimentary Pharmacology & Therapeutics 2019; 49(5): 516 doi: 10.1111/apt.15163
17
Gustavo Castaño, Cristina Etchart, Silvia Sookoian. Vitamin A toxicity in a physical culturist patient: A case report and review of the literatureAnnals of Hepatology 2006; 5(4): 293 doi: 10.1016/S1665-2681(19)31992-1
18
Gustavo O. Castano, Silvia C. Sookoian. Angiotensin II type 1 receptor blockade in early cirrhosisJournal of Hepatology 2007; 47(3): 426 doi: 10.1016/j.jhep.2007.06.007
19
Ling-Zu Kong, Nisansala Chandimali, Ying-Hao Han, Dong-Ho Lee, Ji-Su Kim, Sun-Uk Kim, Tae-Don Kim, Dong Kee Jeong, Hu-Nan Sun, Dong Sun Lee, Taeho Kwon. Pathogenesis, Early Diagnosis, and Therapeutic Management of Alcoholic Liver DiseaseInternational Journal of Molecular Sciences 2019; 20(11): 2712 doi: 10.3390/ijms20112712
20
Wilma Debernardi-Venon, Silvia Martini, Fiorella Biasi, Barbara Vizio, Angela Termine, Giuseppe Poli, Franco Brunello, Carlo Alessandria, Renato Bonardi, Giorgio Saracco, Mario Rizzetto, Alfredo Marzano. AT1 receptor antagonist Candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markersJournal of Hepatology 2007; 46(6): 1026 doi: 10.1016/j.jhep.2007.01.017
21
M. Raimbault, H. Veillon, F. Oberti, P. Calès. Médicaments ayant un effet sur la fibrose hépatiqueJournal Africain d'Hépato-Gastroentérologie 2007; 1(3-4): 110 doi: 10.1007/s12157-008-0031-3
22
Lakmie S. Gunarathne, Peter W. Angus, Chandana B. Herath. Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive RatsFrontiers in Physiology 2019; 10 doi: 10.3389/fphys.2019.01169
23
Gaeun Kim, Juyoung Kim, Yoo Li Lim, Moon Young Kim, Soon Koo Baik. Renin–angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic reviewHepatology International 2016; 10(5): 819 doi: 10.1007/s12072-016-9705-x
24
Angela Douglass, Karen Wallace, Matthew Koruth, Caroline Barelle, Andrew J. Porter, Matthew C. Wright. Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapyHepatology International 2008; 2(4) doi: 10.1007/s12072-008-9093-y
25
Li Gu, Yahui Zhu, Maiya Lee, Albert Nguyen, Nicolas T. Ryujin, Jian Yu Huang, Shusil K. Pandit, Shadi Chamseddine, Lianchun Xiao, Yehia I. Mohamed, Ahmed O. Kaseb, Michael Karin, Shabnam Shalapour. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cellsProceedings of the National Academy of Sciences 2023; 120(19) doi: 10.1073/pnas.2300706120
26
Keshvad Hedayatyanfard, Nazgol‐Sadat Haddadi, Seyed Ali Ziai, Hossein Karim, Feizollah Niazi, Ulrike Muscha Steckelings, Behnam Habibi, Ali Modarressi, Ahmad‐Reza Dehpour. The renin‐angiotensin system in cutaneous hypertrophic scar and keloid formationExperimental Dermatology 2020; 29(9): 902 doi: 10.1111/exd.14154
27
Suchithra Poilil Surendran, Reju George Thomas, Myeong Ju Moon, Rayoung Park, Jae Hyuk Lee, Yong Yeon Jeong. A bilirubin-conjugated chitosan nanotheranostics system as a platform for reactive oxygen species stimuli-responsive hepatic fibrosis therapyActa Biomaterialia 2020; 116: 356 doi: 10.1016/j.actbio.2020.09.014
28
Russell Snyder, Thomas Thekkumkara. 13-cis-Retinoic acid specific down-regulation of angiotensin type 1 receptor in rat liver epithelial and aortic smooth muscle cellsJournal of Molecular Endocrinology 2012; 48(2): 99 doi: 10.1530/JME-11-0095
29
M Kamruzzman Munshi, Mohammad N Uddin, Shannon S Glaser. The role of the renin–angiotensin system in liver fibrosisExperimental Biology and Medicine 2011; 236(5): 557 doi: 10.1258/ebm.2011.010375
30
Moran Elbaz, Nurit Yanay, Shlomit Aga‐Mizrachi, Zivia Brunschwig, Ibaa Kassis, Keren Ettinger, Vivian Barak, Yoram Nevo. Losartan, a therapeutic candidate in congenital muscular dystrophy: Studies in the dy2J/dy2J MouseAnnals of Neurology 2012; 71(5): 699 doi: 10.1002/ana.22694
31
Hala M. Raslan, Khalda S. Amr, Yasser A. Elhosary, Wafaa M. Ezzat, Nour A. Abdullah, Hassan E. El-Batae. Possible role of angiotensin-converting enzyme polymorphism on progression of hepatic fibrosis in chronic hepatitis C virus infectionTransactions of the Royal Society of Tropical Medicine and Hygiene 2011; 105(7): 396 doi: 10.1016/j.trstmh.2011.03.005
32
Jessica M. Motherwell, Connor P. Dolan, Sergey S. Kanovka, Jorge B. Edwards, Sarah R. Franco, Naveena B. Janakiram, Michael S. Valerio, Stephen M. Goldman, Christopher L. Dearth. Effects of Adjunct Antifibrotic Treatment within a Regenerative Rehabilitation Paradigm for Volumetric Muscle LossInternational Journal of Molecular Sciences 2023; 24(4): 3564 doi: 10.3390/ijms24043564
33
Carlos J. Pirola, Silvia Sookoian. Non‐alcoholic fatty liver disease mediates the effect of obesity on arterial hypertensionLiver International 2023; 43(10): 2167 doi: 10.1111/liv.15643
34
Puneeta Tandon, Juan G. Abraldes, Annalisa Berzigotti, Juan Carlos Garcia-Pagan, Jaime Bosch. Renin–angiotensin–aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysisJournal of Hepatology 2010; 53(2): 273 doi: 10.1016/j.jhep.2010.03.013
35
Fiona Oakley, Derek A. Mann. Stellate Cells in Health and Disease2015; : 251 doi: 10.1016/B978-0-12-800134-9.00015-4
36
J. Heller, B. Appenrodt, M. Schepke, T. Sauerbruch. Varizenblutung bei Patienten mit LeberzirrhoseDer Gastroenterologe 2007; 2(4): 238 doi: 10.1007/s11377-007-0089-2
37
John S Lubel, Chandana B Herath, Louise M Burrell, Peter W Angus. Liver disease and the renin–angiotensin system: Recent discoveries and clinical implicationsJournal of Gastroenterology and Hepatology 2008; 23(9): 1327 doi: 10.1111/j.1440-1746.2008.05461.x
38
T. Sauerbruch, J. Trebicka. Pathogenesis and Clinical Practice in Gastroenterology2008; 160: 233 doi: 10.1007/978-1-4020-8767-7_22
39
Kristian Aquilina, Catherine Hobbs, Alexander Tucker, Andrew Whitelaw, Marianne Thoresen. Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model?Acta Paediatrica 2008; 97(9): 1181 doi: 10.1111/j.1651-2227.2008.00903.x
40
George B Goh, Mangesh R Pagadala, Jaividhya Dasarathy, Aynur Unalp‐Arida, Ruth Sargent, Carol Hawkins, Achuthan Sourianarayanane, Amer Khiyami, Lisa Yerian, Rish Pai, Arthur J McCullough, Srinivasan Dasarathy. Renin‐angiotensin system and fibrosis in non‐alcoholic fatty liver diseaseLiver International 2015; 35(3): 979 doi: 10.1111/liv.12611
41
Zuo-Wei Ning, Xiao-Ying Luo, Guo-Zhen Wang, Yang Li, Miao-Xia Pan, Ren-Qiang Yang, Xu-Guang Ling, Shan Huang, Xiao-Xin Ma, Si-Yi Jin, Dan Wang, Xu Li. MicroRNA-21 Mediates Angiotensin II-Induced Liver Fibrosis by Activating NLRP3 Inflammasome/IL-1β Axis via Targeting Smad7 and Spry1Antioxidants & Redox Signaling 2017; 27(1): 1 doi: 10.1089/ars.2016.6669
42
Ghulam Abbas, Marina G Silveira, Keith D Lindor. Hepatic Fibrosis and the Renin-Angiotensin SystemAmerican Journal of Therapeutics 2011; 18(6): e202 doi: 10.1097/MJT.0b013e3181df8df5
43
Abd Elkhalek Hamed, Medhat Elsahar, Nadia M. Elwan, Sarah El-Nakeep, Mervat Naguib, Hanan Hamed Soliman, Ashraf Ahmed Aboubakr, Amany AbdelMaqsod, Heba Sedrak, Samir N. Assaad, Reda Elwakil, Gamal Esmat, Samira Salh, Taymour Mostafa, Sherif Mogawer, Sameh Emil Sadek, Maha M. Saber, Hanan Ezelarab, Asem Ashraf Mahmoud, Souad Sultan, Mohamed El Kassas, Ehab Kamal, Naglaa M. ElSayed, Shorouk moussa. Managing diabetes and liver disease associationArab Journal of Gastroenterology 2018; 19(4): 166 doi: 10.1016/j.ajg.2018.08.003
44
S. Lemoinne, A. Cadoret, N. Bosselut, C. Housset, D. Wendum, D. Thabut. Fibrose hépatiqueEMC - Hépatologie 2012; 7(4): 1 doi: 10.1016/S1155-1976(12)59788-3
45
Antony Sameh Mansour. Autoregulation: mediators and renin–angiotensin system in diseases and treatmentsFuture Journal of Pharmaceutical Sciences 2023; 9(1) doi: 10.1186/s43094-023-00482-4
46
Ahmed Sadek, Ahmed M. Abd El Hady, Hammam Olfat, Afaf A. Abd El Hady, Wafaa Wafy, Moushira Zaki, Eman R. Youness. Effect of ozone gas on viral kinetics and liver histopathology in hepatitis C patientsJournal of Complementary and Integrative Medicine 2024; 21(1): 131 doi: 10.1515/jcim-2023-0239
47
Moon Young Kim, Mee Yon Cho, Soon Koo Baik, Phil Ho Jeong, Ki Tae Suk, Yoon Ok Jang, Chang Jin Yea, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Byung Su Yoo, Jang Young Kim, Min Seob Eom, Seung Hwan Cha, Sei Jin Chang. Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ A randomized open‐label controlled studyLiver International 2012; 32(6): 977 doi: 10.1111/j.1478-3231.2012.02774.x
48
Kwang Yong Shim, Young Woo Eom, Moon Young Kim, Seong Hee Kang, Soon Koo Baik. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertensionThe Korean Journal of Internal Medicine 2018; 33(3): 453 doi: 10.3904/kjim.2017.317
49
Jordi Colmenero, Ramón Bataller, Pau Sancho-Bru, Marlene Domínguez, Montserrat Moreno, Xavier Forns, Miquel Bruguera, Vicente Arroyo, David A. Brenner, Pere Ginès. Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis CAmerican Journal of Physiology-Gastrointestinal and Liver Physiology 2009; 297(4): G726 doi: 10.1152/ajpgi.00162.2009
50
Anureet K. Shah, Sushma Yadav, Hoda Yeganehjoo. The Renin Angiotensin System in Cancer, Lung, Liver and Infectious DiseasesAdvances in Biochemistry in Health and Disease 2023; 25: 3 doi: 10.1007/978-3-031-23621-1_1
51
Michaela Granzow, Robert Schierwagen, Sabine Klein, Benita Kowallick, Sebastian Huss, Markus Linhart, Irela G. Reza Mazar, Jan Görtzen, Annabelle Vogt, Frank A. Schildberg, Maria A. Gonzalez-Carmona, Alexandra Wojtalla, Benjamin Krämer, Jacob Nattermann, Sören V. Siegmund, Nikos Werner, Dieter O. Fürst, Wim Laleman, Percy Knolle, Vijay H. Shah, Tilman Sauerbruch, Jonel Trebicka. Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosisHepatology 2014; 60(1): 334 doi: 10.1002/hep.27117
52
Silvia Sookoian, Carlos J Pirola. Repurposing drugs to target nonalcoholic steatohepatitisWorld Journal of Gastroenterology 2019; 25(15): 1783-1796 doi: 10.3748/wjg.v25.i15.1783
53
Yating Li, Hong Xu, Wenrui Wu, Jianzhong Ye, Daiqiong Fang, Ding Shi, Lanjuan Li. Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysisOncotarget 2018; 9(35): 24155 doi: 10.18632/oncotarget.23816
54
P. Calès, J. Boursier, J. Chaigneau, F. Oberti, M.-C. Rousselet. Treatment of liver fibrosis: Clinical aspectsGastroentérologie Clinique et Biologique 2009; 33(10-11): 958 doi: 10.1016/j.gcb.2009.07.020
55
Paul Manka, Amos Zeller, Wing-Kin Syn. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment ModalitiesDrugs 2019; 79(9): 903 doi: 10.1007/s40265-019-01126-9
56
Abd Elkhalek Hamed. The association between diabetes and liver disease: The need for a consensusArab Journal of Gastroenterology 2014; 15(3-4): 166 doi: 10.1016/j.ajg.2014.09.002
57
Sarkawt Hamad, Ismail Maulood. Hemodynamic and renal effects of bosentan and losartan in 2k1c hypertensive rats.Journal of Zankoy Sulaimani - Part A 2016; 18(2): 63 doi: 10.17656/jzs.10504
58
Qianqian Zhu, Na Li, Fang Li, Zhihua Zhou, Qunying Han, Yi Lv, Jiao Sang, Zhengwen Liu. Therapeutic effect of renin angiotensin system inhibitors on liver fibrosisJournal of the Renin-Angiotensin-Aldosterone System 2016; 17(1): 147032031662871 doi: 10.1177/1470320316628717